Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

Goto Joyce

2. Date of Event Requiring Statement (MM/DD/YYYY) 10/10/2018

3. Issuer Name and Ticker or Trading Symbol

BioPharmX Corp [BPMX]

(Last) (First) (Middle)

1505 ADAMS DRIVE, SUITE D

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director _____ 10% Owner
_____ Officer (give title below) ___ X ___ Other (specify below)
/ Chief Accounting Officer

(Street)

MENLO PARK, CA 94025

(City) (State) (Zip)

5. If Amendment, Date Original Filed (MM/DD/YYYY)

6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

*Table II - Derivative Securities Beneficially Owned ( e.g.* , puts, calls, warrants, options, convertible securities)**
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Option to purchase common stock ⁽¹⁾	4/13/2016	4/13/2025	Common stock	150000	$1.67	D
Option to purchase common stock ⁽¹⁾	7/1/2017	7/1/2026	Common stock	31000	$0.65	D
Option to purchase common stock ⁽¹⁾	7/21/2017	7/21/2026	Common stock	99000	$0.62	D
Option to purchase common stock ⁽¹⁾	12/8/2017	12/8/2026	Common stock	90000	$0.42	D
Option to purchase common stock ⁽¹⁾	4/18/2018	4/18/2027	Common stock	225000	$0.74	D
Option to purchase common stock ⁽²⁾	1/31/2018	12/20/2027	Common stock	400000	$0.1	D
Option to purchase common stock ⁽²⁾	1/31/2018	12/20/2027	Common stock	184000	$0.2	D

Explanation of Responses:
(1)	This option vests as to 25% of the shares subject to the option on the first anniversary date of the grant with an additional 1/36th of the remaining shares vesting on the last day of each full calendar month thereafter.
(2)	This option vests and becomes exercisable ratably over 36 months.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Goto Joyce 1505 ADAMS DRIVE, SUITE D MENLO PARK, CA 94025				Chief Accounting Officer

Signatures
/s/Joyce Goto		10/12/2018
^** Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Grafico Azioni BioPharmX (AMEX:BPMX)
Storico
Da Giu 2024 a Lug 2024

Grafico Azioni BioPharmX (AMEX:BPMX)
Storico
Da Lug 2023 a Lug 2024

BPMX BioPharmX Corporation